The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
You remember WAG, them sitting around for weeks waiting for the EU to approve the LFT only to be told on Twitter that the third party contracted to do it had forgotten to send their application in? Do you remember the Block Listing Six Monthly Return eleven days ago? Did you notice that the abstract for AACR 2024 said 51mg/m² not 54mg/m²? And many more examples. Hopefully the new regime will tighten up on this poor oversight. One can only hope that official submissions to the likes of the FDA don't have basic errors like these in them.
Hopefully, but their lack of oversight I wouldn't be surprised. I always remember this from a professional development session at work:
It was a job that anyone could do but everyone thought that someone would do it so in the end no one did it.
Their previous method has been to announce the 1st/3rd patient dosed when starting/restarting a trial (which Alan had done, with an anticipated SDMC review by the end of April), then at each SDMC decision to escalate the dose. It could be of course that no one was tasked with scheduling an SDMC meeting.
Still nothing. It's beginning to look like a patient has dropped out.
That's a lousy poem
People at that level are frequent-flyer members.
"The Chief Executive has direct charge of the Group on a day-to-day basis and is accountable to the Board for the financial and operational performance of the Group."
That's as may be but the CEO doesn't do it all him-/herself. He/she is reliant upon the other board members in their official capacities to give advice and guidance and, themselves and through their subordinates, to carry out actions.
ADCs consist of a warhead linked covalently to an antibody targetted to some antigen marker on specific types of cancer cells. The weak part of this is the covalent bond which can be cleaved by enzymes or acid (change in pH). Consequently these ADCs tend to fall apart before they get to the cancer cells they are designed to target. This weakness manifests itself as the same warhead producing the same side effects (off-site toxicity), irrespective of the antibody it is bound to.
Enter highly targetted FAP-specific pre|CISION substrates🤺...
That would be my hope also. The interesting part is the inclusion of 'quantifying'. However this isn't the first diagnostic patent involving Affimers, if that's what 'polypeptides' is specifically referring to.
Patent titles are deliberately obtuse. Take for example the one published in Journal 7018 on 22 November 2023: 'Constucts'.😂 Typical Avacta.😕
https://www.ipo.gov.uk/p-pj?startYear=2020&startMonth=January&startDay=29th+-+6819&endYear=2024&endMonth=May&endDay=1st+-+7041&filter=Avacta&perPage=10&sort=Publication+Date
Come off it gje. It was just a bit of pillow talk and should be left private.
Some people post a lot but also produce a lot of Scheiße.
Q2W C1 SDMC review
"The Group’s strategy is to divest the Diagnostics Division to create a pure-play oncology biopharmaceutical company in a manner which maximises value and strategic benefits for shareholders.
With a balanced business and capital allocation model: a high-value oncology pipeline supported by a revenue generating, fast-growing diagnostics business, Avacta seeks to create long-term shareholder value alongside patient benefit."
Oh dear
"Avacta has two divisions: an clinical stage oncology biotech division" Oh dear.
Soon Alan will be but a mere bad dream we all wished we hadn't had.
Completely disagree with you Bridgedogg1.
"Building out a diagnostics division made perfect sense"? For a company that had no Dx experience and, as it turned out, no skill? Pull the other one. Dx has STILL not produced anything. "If", if, if. Name me one successful Dx business worth more than a successful Tx business.
Dx is NOT projected by Avacta to be "be cash generative in 6 months". To say so is a blatant falsehood.
"The problem is the therapeutics is draining all the cash." Firstly, Dx is draining the cash for no perceivable future benefit. Secondly, it's a given that that's what Tx does until profitable.
I used to think you were sensible. Now I think you're an idiot.
I wonder whether Phase 1 will be used to produce Avacta's first peer reviewed paper. Sometime this year, next year, somewhen.
Random
AS did the first webinar with TP (jointly with Vox Markets) back in June 2020. Worth a listen, at least to the start, to hear barrow boy James Pope.
See my posts on the 'Onwards and upwards' thread.
(Proof reading was regarded as heresy in the Alan regime.)